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 Abstract 
Hepatitis C virus (HCV) is a major pathogen with approximately 3% of the world’s 
population (over 170 million) infected. Epidemiological studies have shown HCV is 
associated with an increased risk of cardiovascular and cerebrovascular mortality as well as 
peripheral arterial disease. This is despite HCV inducing an ostensibly favourable lipid profile 
with accompanying low classical risk score for atherosclerosis (AS).  
We discuss possible factors involved in the aetiopathogenesis of atherosclerosis in chronic 
HCV and hypothesise that an important mechanism underlying the development of AS is the 
presence of circulating low-density immune complexes that induce an inflammatory response. 
We suggest that HCV particles may be inducing an antibody response to lipoproteins present 
in the lipo-viral particles and sub-viral particles – a concept similar to the more general 
‘autoantibody’ response to modified LDL. 
After virologic cure some AS risk factors will recede but an increase in serum cholesterol 
could result in progression of early atherosclerotic lesions, leaving a legacy from persistent 
HCV infection that has clinical and therapeutic implications.  
 
 
Introduction 
Atherosclerosis (AS) is the underlying cause of heart attack, ischaemic stroke and 
peripheral vascular disease and hence is a leading cause of morbidity and mortality. 
Traditional risk factor assessment has focused on parameters identified in 
epidemiological studies such as the Framingham Heart Study (FHS) (age, 
hypertension, cholesterol, family history, and cigarette smoking). However, a sizeable 
minority of patients suffering from atherosclerosis do not harbour the classical risk 
factors. Other predisposing factors appear to contribute to the disease process 
including chronic viral infections (1-3). 
Lifelong exposure to raised concentrations of LDL cholesterol (LDL-C) increases 
cardiovascular event rates and the use of statin therapy as an adjunct to diet, exercise, 
and smoking cessation has proven highly effective in reducing the population burden 
of disease associated with hyperlipidaemia (4). Conversely, rare inherited conditions 
such as hypobetalipoproteinemia and PCSK9 loss-of-function mutations have shown 
that very low LDL levels are associated with reduced risk of cardiovascular disease 
(5).  
The human hepacivirus, hepatitis C virus (HCV) is a major pathogen with 
approximately 3% of the world’s population (over 170 million) infected. 70% of those 
infected fail to clear the virus and are at risk of developing liver complications, 
mainly cirrhosis and liver cancer.  
HCV affects cholesterol homeostasis and chronic infection is associated with a 
decrease in serum levels of total cholesterol, LDL-C and apolipoprotein B (apoB - the 
main protein constituent of LDL and very-low-density lipoprotein (VLDL)). These 
changes are more marked in HCV genotype 3 infection and effective anti-viral 
treatment results in their reversal [reviewed in (6, 7)]. Despite this apparently 
favourable lipid profile, HCV infection is associated with an increased risk of 
atherosclerosis and its clinical manifestations (8). 
 
HCV and atherosclerosis 
It became apparent over a decade ago that HCV might be considered as a risk factor 
for the development of coronary artery disease (CAD) (9). In 2012, a systematic 
review of the literature suggested an increased risk of CAD in HCV-infected 
individuals (10). Subsequently myocardial perfusion defects have been found in 87% 
of the patients with chronic hepatitis C which improved with viral eradication (11).  
Carotid intima-media thickness (IMT) has been used to assess the extent of 
atherosclerosis and studies have shown that, after adjustment for classical 
cardiovascular risk factors, those with chronic HCV infection have raised IMT (12) 
and this occurs at an earlier age (13). HCV RNA has been found in carotid plaques 
(14).  Recent meta-analyses have shown that HCV infection increases the risk of 
developing carotid intima media thickening by approximately 4-fold (15); other 
studies found an increased risk of carotid atherosclerosis and of stroke [pooled OR of 
1.76 & 1.97 respectively] (16, 17).  
Although some of the earlier studies did not identify an association between HCV and 
cardiovascular morbidity [reviewed in (18)], an increasing number of large 
epidemiological studies do confirm an association of HCV infection with 
atherosclerosis (19-22) (Table). One recent retrospective cohort study found that both 
HCV antibody positivity [n = 8,251 individuals] and HCV RNA positivity [1,434 
individuals] were independent risk factors for coronary heart disease events [OR 1.32 
and 1.52 respectively], when compared to 14,799 HCV negative patients (23). This 
study concluded that lipid profile did not appear to be a good cardiovascular disease 
risk stratification tool in patients with HCV infection. Another recent study has also 
concluded that the Framingham Risk Score (FRS) may underestimate coronary heart 
disease (CHD) risk in both HCV-monoinfected and HIV/HCV co-infected persons 
(24).  
In a community based prospective cohort study of 23,665 Taiwanese residents (aged 
30 to 65 years) the hazard ratio of cerebrovascular death was 2.18 (95% CI: 1.50 to 
3.16) for anti-HCV seropositives after adjustment for conventional risk factors of 
cerebrovascular disease. Compared with participants seronegative for anti-HCV as the 
referent, the multivariate-adjusted hazard ratio was 1.40, 2.36 and 2.82, respectively, 
for anti-HCV-seropositive participants with undetectable, low, and high serum levels 
of HCV RNA (P<0.001 for trend) (25). 
Another manifestation of atherosclerosis is peripheral vascular disease and, again, a 
population based study in Taiwan of 7,641 HCV-infected patients compared to 30,564 
matched controls has found a higher adjusted risk of peripheral arterial disease in the 
HCV-infected group of 1.43 which increased with age to 11.7 in those aged 65 years 
and above (26). 
 Table: 
Reference No. of participants Atherosclerosis risk 
Guiltinan AM et al. 2008 
(19) 
10,259 HCV antibody-positive 
(HCV+) vs 10,259 HCV 
antibody-negative (HCV-) 
blood donors 
Increase in cardiovascular mortality  (HR = 
2.21, 95% CI: 1.41 to 3.46) 
Butt AA et al. 2009 (20) 82,083 HCV-infected vs 89,582 
HCV-uninfected subjects. 
Higher risk of CAD (HR = 1.25, 95% CI: 1.20 to 
1.30). 
Freiberg MS et al. 2011 
(21) 
8,579 participants (9% 
HIV+HCV+ vs 28% HIV+ HCV-)  
HIV+HCV+ had higher risk of CHD (HR = 2.03,  
95% CI:, 1.28 to 3.21) 
Lin MS et al. 2014  (22) 5,015 eligible Taiwanese 
residents,  age > 40 years 
HCV+ had 1.76-fold risk of ischemic ECG when 
compared with non-HCV  
Pothineni NV et al. 2014 
(23) 
8,251 HCV antibody positive, 
1,434 HCV RNA positive, vs 
14,799 HCV negative patients. 
Increased risk of incident CHD events in HCV 
antibody-positive (OR = 1.32, 95% CI: 1.09 to 
1.60, p <0.001) and HCV RNA positive (OR = 
1.59, 95% CI: 1.13 to 2.26, p <0.001. 
Lee MH et al.2010  (25) 23,665 residents (aged 30 to 
65 years), 255 cerebrovascular 
deaths during 382,011 person-
years of follow-up. 
Increase in cerebrovascular death (HR = 2.18 
(95% CI: 1.50 to 3.16) for HCV-antibody 
positive. 
Hsu YH et al. 2015 (26) 7,641 HCV-infected patients 
and 30,564 matched controls. 
Increase in peripheral arterial disease in HCV-
infected patients (HR = 1.43, (95% CI=1.23 to 
1.67) compared with non-HCV patients 
 
 
Aetiopathogenesis of HCV-associated atherosclerosis 
As elevated LDL-C does not play a role during persistent HCV infection and FRS 
underestimates AS risk in these patients, it is important to examine what other factors 
may be playing a role. HCV infection may represent a new paradigm and reveal 
mechanism(s) that are relevant in up to 20% of patients with coronary heart disease 
who do not have conventional risk factors (27).  
It is likely that the aetiopathogeneis of AS in HCV infection is multifactorial and 
pathogenic mechanism(s) may include: 
1. Endothelial dysfunction: In the last decades the endothelium has emerged as 
the key regulator of vascular homeostasis. Endothelial dysfunction and 
inflammation are linked to the pathogenesis of atherosclerotic disease. 
Increased risk for CV events is associated with increased levels of cytokines, 
cell-adhesion molecules, P-selectin and E-selectin and acute phase reactants, 
such a high-sensitivity C-reactive protein (CRP). Platelet-endothelial 
interactions occur in early atherosclerosis. Soluble P-selectin, a marker of in 
vivo platelet activation, is a cellular adhesion molecule that has been shown to 
be crucial in development of CHD. A positive linear association between P-
selectin levels and rate of incident CHD after adjustment for traditional risk 
factors has been observed (28).  
HCV infection of endothelial cells (29) may promote endothelial dysfunction 
and early atherogenesis. Patients with chronic hepatitis C infection have 
increased levels of several inflammatory markers including high-sensitivity 
CRP, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion 
molecule-1, soluble E-selectin and P-selectin (30)(31).  
 
2. Lipid disturbances: HCV cause profound changes in lipid metabolism 
including a raised Cholesteryl Ester Transfer Protein (CETP) (32).  CETP 
promotes the transfer of cholesteryl esters from HDL to very low-density 
lipoprotein and LDL. Human genetic studies and human cohort studies have 
concluded that CETP gene polymorphisms associated with decreased CETP 
activity are accompanied by a significantly lower risk of atherosclerotic 
cardiovascular disease. 
CETP inhibition raises HDL-C levels, long touted as the "good cholesterol", 
and is being evaluated for treatment of atherosclerosis (33). CETP inhibitors, 
as monotherapy or with statins, significantly reduce the concentrations of 
atherogenic apoB-containing lipoproteins, including Lp(a) (34).  
 
3. Metabolic disturbances: Positive associations have been observed between 
CVD and type 2 diabetes mellitus (DM), but their causal relationship has not 
been clarified. Epidemiological data indicate a risk for development of insulin 
resistance (IR) particularly in patients with hepatitis C virus (HCV) genotype 
1 infection and, ultimately, overt DM (35). However a recent large population-
based study has not confirmed an appreciable excess risk of DM (36). 
Eradication of HCV improves IR and insulin hypersecretion, as well as high 
baseline insulin resistance (HOMA-IR >2.5) (37), so this risk factor should 
resolve after virologic cure. 
 
4. MicroRNAs (miRNAs) are small noncoding RNAs involved in intercellular 
communication; they have been shown to circulate in the bloodstream in 
stable forms. In the past years specific miRNA expression patterns have been 
linked to the development of atherosclerosis (38). HCV infection alters the 
expression of host miRNAs and, in turn, miRNAs are able to regulate HCV 
replication (39).  It has been proposed that miR-122, the most abundant liver 
miRNA which plays a central role in the maintenance of lipid homeostasis, 
may constitute a novel biomarker for cardiovascular disease (40).  
MiR-122 has been shown to modulate hepatic production of apoB-containing 
low density lipoprotein (41) and is an important host factor for hepatitis C 
virus replication. Administration of miravirsen, an anti-miR-122 
oligonucleotide, has been shown to result in a dose dependent and prolonged 
decrease in HCV RNA levels in chronic hepatitis C patients (42). The role of 
the deranged miRNAs induced by HCV in the aetiopathogenesis of HCV-
associated AS is unclear. 
 
5. Autoimmunity: (Auto)immune reactivity to a range of autoantigens, but most 
prominently modified LDL (mLDL), is a marker of human cardiovascular 
disease and in experimental models plays a significant role in promoting 
atherosclerotic plaque progression.  Both pathogenic and protective immunity 
to apoB have been identified (43) but it appears that, in humans, the humoral 
immune response to mLDL is pathogenic rather than protective[reviewed in 
(44)].  B cell-activating factor (BAFF) is a tumour necrosis factor-family 
cytokine that plays a key role in generating and maintaining the mature B-cell 
pool. BAFF is known to be involved in the occurrence of autoimmune 
diseases. BAFF signaling via the B-cell activating factor receptor (BAFFR) is 
essential for B2 cell survival; these cells seem to be proatherogenic. In chronic 
HCV infection, elevation in serum BAFFhas been reported to be associated 
with HCV-related vasculitis (p<0.0001), and with the presence of 
anticardiolipin Abs and of cryoglobulins. (45).  
Modified LDL-containing immune complexes (mLDL-IC) play a role in the 
formation of early atherosclerotic lesions [reviewed in (46, 47)]. Infectious 
HCV lipo-viral particles (LVPs) found in the low density fraction of blood 
contain HCV-RNA + structural viral proteins + apoB + apoE + apoCII + 
triglycerides + cholesterol + phospholipids; the majority are complexed with 
IgG and IgM (48). However it is now clear that LVPs are a mixed population 
of particles, comprising predominantly subviral particles which outnumber 
HCV-RNA containing particles by > 1x 10 6. These HCV envelope 
glycoprotein-positive lipoproteins represent a distinct class of modified 
lipoproteins within the TRL family (49) and are present in immune-complexes 
in patients with chronic HCV. We hypothesise that an important mechanism 
underlying the development of AS in HCV infection is the presence of these 
circulating low-density immune complexes that are taken up by monocytes via 
Fc gamma receptors, inducing an inflammatory response (Figure). HCV has 
been found in cutaneous vasculitic lesions in complex with IgM and IgG in 
patients with type II cryoglobulinemia (50).  
Atherosclerosis initiation and progression are thought to be primarily mediated 
by cells of the monocyte/macrophage lineage (51, 52). The uptake of mLDL-
immune complexes by human macrophages leads to massive cholesterol ester 
accumulation, cytokine release and overexpression of the LDL receptor 
(LDLR) (53). LDLR plays a role in the life-cycle of HCV (54) and HCV 
infection induces higher expression of LDLR on lymphocytes and monocytes 
(55).  Monocytes, macrophages and dendritic cells can be infected by HCV, so 
a direct pro-inflammatory effect may also contribute to AS. In addition HCV 
infection of monocytes increases immunoregulatory galectin-9 production and 
there is emerging evidence for a role for galectins in AS (56).  
 
Virologic cure and atherosclerosis 
Virologic cure is now achievable in the vast majority of patients treated with direct-
acting anti-viral (DAA) therapy and reduces the risk of liver disease progression (57).  
The effect of virologic cure is on AS progression is however unknown but a 
significant AS risk has also been reported in those that are HCV antibody positive but 
HCV RNA negative. 
 
Early atherosclerotic lesions appear to be a feature of chronic HCV infection, despite 
the virus inducing an apparently favourable lipid profile.  AS risk increases with age 
and therefore, presumably, duration of chronic viral infection. Current evidence 
indicates that the risk of a person with chronic hepatitis C developing coronary 
atherosclerosis is about triple the risk in uninfected persons (OR = 3.06, 95% 
CI = 1.99-4.72) (58). Virologic cure will be lead to improvements in some AS risk 
factors outlined above such as insulin resistance (37) and the consequences of direct 
infection of endothelial cells and monocytes but others factors such as HCV-induced 
autoimmunity to mLDL may persist. This is suggested by the observation in 
chimpanzees that the frequency of T-regulatory  cells and the extent of suppression is 
as high in those that recovered from HCV as in persistently HCV-infected animals, 
suggesting ongoing control of an ‘autoimmune’ response (59).  
In addition virologic cure will result in increases in serum cholesterol and LDL-C 
(60), creating a combination of circumstances that will aggravate early atherosclerotic 
lesions. This ‘perfect storm’ for AS progression after virologic cure has important 
clinical and therapeutic implications.  Not only should patients be monitored for AS 
but statin therapy should also be considered. This is particularly pertinent if an 
autoimmune response to mLDL persists after cure as a recent study has shown that 
simvastatin therapy in the CAD patients lowers small LDL-IgG-IC levels to a greater 
extent than LDL-cholesterol levels (61). 
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Figure legend 
(Auto)immune reactivity to a host antigen(s) within HCV lipo-viral and sub-viral particles 
may play a role in promoting atherosclerosis.  
 
